Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors

McClellan, Kristen; Chen, Emerson Y.; Kardosh, Adel; Lopez, Charles D.; Rivero, Jaydira del; Mallak, Nadine; Rocha, Flavio G.; Koethe, Yilun; Pommier, Rodney F.; Mittra, Erik; Pegna, Guillaume J.

doi:10.3390/cancers14194769

Cited by 5 publications

(7 citation statements)

References 155 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1), lung, and other cancers, or overexpression of surface receptors, e.g., [ 68 Ga]PSMA in prostate cancer 14 (Fig. 2) or [ 68 Ga]DOTATATE in neuroendocrine tumors, 15 bone-specific agents are incorporated into the mineral phase of bone secondary to increased local blood flow and mineralization 16 . The same principles hold for targeting bone metastases with radionuclide therapeutic agents labeled with α or β emitters.…”

Section: Pathophysiology Of Bone Metastases Related To Molecular Imag...mentioning

confidence: 99%

“…Several single-photon oncologic tracers have the ability to detect and monitor therapy response in bone metastases and usually have the additional benefit of detecting soft tissue disease as well. These radiopharmaceuticals tend to be disease-specific, for example, [ 131 I]iodine in thyroid cancer or ( 111 In]octreotide and [ 99m Tc]EDDA-HYNIC-TOC in neuroendocrine tumors, 43,44 often acting as theranostic agents for planning and assessing response to radionuclide therapy with respective therapeutic radiopharmaceuticals, although equivalent diagnostic PET isotopes also exist, e.g., [124 I]iodine 45 and [ 68 Ga]DOTATATE 15 …”

Section: Pathophysiology Of Bone Metastases Related To Molecular Imag...mentioning

confidence: 99%

“…PSMA PET ligands can also be used for measuring treatment response 62 and to determine eligibility for radionuclide therapy with [ 177 Lu]PSMA 10 . An additional benefit of the above PET radiotracers is the ability to detect and monitor nonosseous metastatic disease 15 …”

Section: Pathophysiology Of Bone Metastases Related To Molecular Imag...mentioning

confidence: 99%

“…Other tumor-directed therapies like 131 I and 177 Lu-DOTATATE 15 treat bone and soft tissue metastases in their respective targets. Several potential therapies are in development, 104 including α-based therapies targeting PSMA 14 and somatostatin receptor and α- or β-emitting conjugates with monoclonal antibodies targeting FGFR3 (overexpressed in bladder cancer and multiple myeloma), MC1R (melanoma), and FAP, 64 CD46, and CCK2 (multiple tumor types).…”

Section: Pathophysiology Of Bone Metastases Related To Molecular Imag...mentioning

confidence: 99%

See 3 more Smart Citations

Bone Metastases

Cook,

Thorpe

2024

Cancer J

View full text Add to dashboard Cite

Bone metastases occur frequently in common malignancies such as breast and prostate cancer. They are responsible for considerable morbidity and skeletal-related events. Fortunately, there are now several systemic, focal, and targeted therapies that can improve quality and length of life, including radionuclide therapies. It is therefore important that bone metastases can be detected as early as possible and that treatment can be accurately and sensitively monitored. Several bone-specific and tumor-specific single-photon emission computed tomography and positron emission tomography molecular imaging agents are available, for detection and monitoring response to systemic therapeutics, as well as theranostic agents to confirm target expression and predict response to radionuclide therapies.

show abstract

Section: Pathophysiology Of Bone Metastases Related To Molecular Imag...mentioning

confidence: 99%

Section: Pathophysiology Of Bone Metastases Related To Molecular Imag...mentioning

confidence: 99%

Section: Pathophysiology Of Bone Metastases Related To Molecular Imag...mentioning

confidence: 99%

Section: Pathophysiology Of Bone Metastases Related To Molecular Imag...mentioning

confidence: 99%

See 2 more Smart Citations

Bone Metastases

Cook,

Thorpe

2024

Cancer J

View full text Add to dashboard Cite

show abstract

“…However, resistance to PRRT may occur, necessitating the exploration of therapeutic alternatives. Mechanisms such as the downregulation or alteration of SSTRs, enhanced DNA damage repair mechanisms, or treatment-induced hypoxia could contribute to PRRT resistance [32,33]. The list of recently developed molecules targeting SSTR2 is presented in Table 1.…”

Section: Pre-existing-based Moleculesmentioning

confidence: 99%

Recent Pre-Clinical Advancements in Nuclear Medicine: Pioneering the Path to a Limitless Future

Echavidre,

Fagret,

Faraggi

et al. 2023

Cancers

View full text Add to dashboard Cite

The theranostic approach in oncology holds significant importance in personalized medicine and stands as an exciting field of molecular medicine. Significant achievements have been made in this field in recent decades, particularly in treating neuroendocrine tumors using 177-Lu-radiolabeled somatostatin analogs and, more recently, in addressing prostate cancer through prostate-specific-membrane-antigen targeted radionuclide therapy. The promising clinical results obtained in these indications paved the way for the further development of this approach. With the continuous discovery of new molecular players in tumorigenesis, the development of novel radiopharmaceuticals, and the potential combination of theranostics agents with immunotherapy, nuclear medicine is poised for significant advancements. The strategy of theranostics in oncology can be categorized into (1) repurposing nuclear medicine agents for other indications, (2) improving existing radiopharmaceuticals, and (3) developing new theranostics agents for tumor-specific antigens. In this review, we provide an overview of theranostic development and shed light on its potential integration into combined treatment strategies.

show abstract

Recent advances in the development of 225Ac- and 211At-labeled radioligands for radiotheranostics

Munekane,

Fuchigami,

Ogawa

2024

ANAL. SCI.

View full text Add to dashboard Cite

Radiotheranostics utilizes a set of radioligands incorporating diagnostic or therapeutic radionuclides to achieve both diagnosis and therapy. Imaging probes using diagnostic radionuclides have been used for systemic cancer imaging. Integration of therapeutic radionuclides into the imaging probes serves as potent agents for radionuclide therapy. Among them, targeted alpha therapy (TAT) is a promising next-generation cancer therapy. The α-particles emitted by the radioligands used in TAT result in a high linear energy transfer over a short range, inducing substantial damage to nearby cells surrounding the binding site. Therefore, the key to successful cancer treatment with minimal side effects by TAT depends on the selective delivery of radioligands to their targets. Recently, TAT agents targeting biomolecules highly expressed in various cancer cells, such as sodium/iodide symporter, norepinephrine transporter, somatostatin receptor, αvβ3 integrin, prostate-specific membrane antigen, fibroblast-activation protein, and human epidermal growth factor receptor 2 have been developed and have made remarkable progress toward clinical application. In this review, we focus on two radionuclides, 225Ac and 211At, which are expected to have a wide range of applications in TAT. We also introduce recent fundamental and clinical studies of radiopharmaceuticals labeled with these radionuclides. Graphical abstract

show abstract

Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors

Cited by 5 publications

References 155 publications

Bone Metastases

Bone Metastases

Recent Pre-Clinical Advancements in Nuclear Medicine: Pioneering the Path to a Limitless Future

Recent advances in the development of 225Ac- and 211At-labeled radioligands for radiotheranostics

Contact Info

Product

Resources

About